Shigeki Miyamoto - Publications

Affiliations: 
University of Wisconsin, Madison, Madison, WI 
Area:
Molecular Biology, Cell Biology, Immunology

51 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. The Journal of Biological Chemistry. PMID 29279332 DOI: 10.1074/jbc.RA117.000667  0.92
2017 Hope C, Emmerich PB, Papadas A, Pagenkopf A, Matkowskyj KA, Van De Hey DR, Payne SN, Clipson L, Callander NS, Hematti P, Miyamoto S, Johnson MG, Deming DA, Asimakopoulos F. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. Journal of Immunology (Baltimore, Md. : 1950). PMID 28754680 DOI: 10.4049/jimmunol.1700529  0.44
2016 Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, Maroulakou I, Callander N, Miyamoto S, Hematti P, Apte SS, Asimakopoulos F. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood. PMID 27259980 DOI: 10.1182/blood-2016-03-705780  0.44
2016 Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S, Zhong X, Pflum N, Jobin P, Kahl BS, Eickhoff JC, Wuerzberger-Davis SM, Miyamoto S, Thomas CJ, Yang DT, et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene. PMID 27157620 DOI: 10.1038/onc.2016.155  0.92
2015 Hwang B, McCool K, Wan J, Wuerzberger-Davis SM, Young EW, Choi EY, Cingolani G, Weaver BA, Miyamoto S. IPO3 mediated nonclassical nuclear import of NEMO drives DNA damage-dependent NF-κB activation. The Journal of Biological Chemistry. PMID 26060253 DOI: 10.1074/jbc.M115.645960  0.48
2015 Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integrative Biology : Quantitative Biosciences From Nano to Macro. 7: 643-54. PMID 25998180 DOI: 10.1039/c5ib00071h  0.48
2015 Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F. Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunology Research. PMID 25941352 DOI: 10.1158/2326-6066.CIR-15-0025-T  0.44
2015 Hwang B, Phan FP, McCool K, Choi EY, You J, Johnson A, Audhya A, Miyamoto S. Quantification of cellular NEMO content and its impact on NF-κB activation by genotoxic stress. Plos One. 10: e0116374. PMID 25742655 DOI: 10.1371/journal.pone.0116374  0.48
2015 Jackson SS, Miyamoto S. Dissecting NF-κB signaling induced by genotoxic agents via genetic complementation of NEMO-deficient 1.3E2 cells. Methods in Molecular Biology (Clifton, N.J.). 1280: 197-215. PMID 25736750 DOI: 10.1007/978-1-4939-2422-6_11  0.48
2015 Jackson SS, Oberley C, Hooper CP, Grindle K, Wuerzberger-Davis S, Wolff J, McCool K, Rui L, Miyamoto S. Withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-κB signaling. Experimental Cell Research. 331: 58-72. PMID 25304104 DOI: 10.1016/j.yexcr.2014.09.034  0.48
2014 Hooper C, Jackson SS, Coughlin EE, Coon JJ, Miyamoto S. Covalent modification of the NF-κB essential modulator (NEMO) by a chemical compound can regulate its ubiquitin binding properties in vitro. The Journal of Biological Chemistry. 289: 33161-74. PMID 25296760 DOI: 10.1074/jbc.M114.582478  0.48
2014 Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemotherapy and Pharmacology. 74: 875-82. PMID 25168296 DOI: 10.1007/s00280-014-2550-5  0.68
2014 Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, ... ... Miyamoto S, et al. DEAD-box helicase DP103 defines metastatic potential of human breast cancers. The Journal of Clinical Investigation. 124: 3807-24. PMID 25083991 DOI: 10.1172/JCI73451  0.48
2014 Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 123: 3305-15. PMID 24723682 DOI: 10.1182/blood-2014-02-554071  0.48
2014 Yang B, Wagner J, Damaschke N, Yao T, Wuerzberger-Davis SM, Lee MH, Svaren J, Miyamoto S, Jarrard DF. A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation. Plos One. 9: e88052. PMID 24558376 DOI: 10.1371/journal.pone.0088052  0.92
2014 Berry SM, Chin EN, Jackson SS, Strotman LN, Goel M, Thompson NE, Alexander CM, Miyamoto S, Burgess RR, Beebe DJ. Weak protein-protein interactions revealed by immiscible filtration assisted by surface tension. Analytical Biochemistry. 447: 133-40. PMID 24215910 DOI: 10.1016/j.ab.2013.10.038  0.48
2013 Jackson SS, Coughlin EE, Coon JJ, Miyamoto S. Identifying post-translational modifications of NEMO by tandem mass spectrometry after high affinity purification. Protein Expression and Purification. 92: 48-53. PMID 24012789 DOI: 10.1016/j.pep.2013.08.020  0.48
2013 Pak C, Miyamoto S. A new alpha in line between KRAS and NF-κB activation? Cancer Discovery. 3: 613-615. PMID 23749528 DOI: 10.1158/2159-8290.CD-13-0193  0.48
2013 Hebron E, Hope C, Kim J, Jensen JL, Flanagan C, Bhatia N, Maroulakou I, Mitsiades C, Miyamoto S, Callander N, Hematti P, Asimakopoulos F. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. British Journal of Haematology. 160: 779-84. PMID 23252623 DOI: 10.1111/bjh.12175  0.48
2012 McCool KW, Miyamoto S. DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out. Immunological Reviews. 246: 311-26. PMID 22435563 DOI: 10.1111/j.1600-065X.2012.01101.x  1
2012 Young EW, Pak C, Kahl BS, Yang DT, Callander NS, Miyamoto S, Beebe DJ. Microscale functional cytomics for studying hematologic cancers. Blood. 119: e76-85. PMID 22262772 DOI: 10.1182/blood-2011-10-384347  0.48
2011 Lee MH, Miyamoto S. Expanding NFκB and SUMO ties. Cell Cycle (Georgetown, Tex.). 10: 3983-4. PMID 22134137 DOI: 10.4161/cc.10.23.18248  0.36
2011 Lee MH, Mabb AM, Gill GB, Yeh ET, Miyamoto S. NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Molecular Cell. 43: 180-91. PMID 21777808 DOI: 10.1016/j.molcel.2011.06.017  0.48
2011 Yang Y, Xia F, Hermance N, Mabb A, Simonson S, Morrissey S, Gandhi P, Munson M, Miyamoto S, Kelliher MA. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Molecular and Cellular Biology. 31: 2774-86. PMID 21606198 DOI: 10.1128/MCB.01139-10  0.4
2011 Wuerzberger-Davis SM, Chen Y, Yang DT, Kearns JD, Bates PW, Lynch C, Ladell NC, Yu M, Podd A, Zeng H, Huang TT, Wen R, Hoffmann A, Wang D, Miyamoto S. Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formation. Immunity. 34: 188-200. PMID 21333553 DOI: 10.1016/j.immuni.2011.01.014  0.48
2010 Wu ZH, Wong ET, Shi Y, Niu J, Chen Z, Miyamoto S, Tergaonkar V. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Molecular Cell. 40: 75-86. PMID 20932476 DOI: 10.1016/j.molcel.2010.09.010  0.48
2010 Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, Miyamoto S. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Molecular Cancer. 9: 176. PMID 20604947 DOI: 10.1186/1476-4598-9-176  0.68
2010 Wuerzberger-Davis SM, Miyamoto S. TAK-ling IKK activation: "Ub" the judge. Science Signaling. 3: pe3. PMID 20086238 DOI: 10.1126/scisignal.3105pe3  0.92
2008 Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Molecular Cancer Research : McR. 6: 1356-64. PMID 18708367 DOI: 10.1158/1541-7786.MCR-08-0108  0.68
2008 Ni CY, Wu ZH, Florence WC, Parekh VV, Arrate MP, Pierce S, Schweitzer B, Van Kaer L, Joyce S, Miyamoto S, Ballard DW, Oltz EM. Cutting edge: K63-linked polyubiquitination of NEMO modulates TLR signaling and inflammation in vivo. Journal of Immunology (Baltimore, Md. : 1950). 180: 7107-11. PMID 18490708  0.48
2008 Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Molecular Cancer. 7: 40. PMID 18489772 DOI: 10.1186/1476-4598-7-40  0.48
2007 Mabb AM, Miyamoto S. SUMO and NF-kappaB ties. Cellular and Molecular Life Sciences : Cmls. 64: 1979-96. PMID 17530464 DOI: 10.1007/s00018-007-7005-2  1
2007 Wuerzberger-Davis SM, Nakamura Y, Seufzer BJ, Miyamoto S. NF-kappaB activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage. Oncogene. 26: 641-51. PMID 16862178 DOI: 10.1038/sj.onc.1209815  0.92
2006 Mabb AM, Wuerzberger-Davis SM, Miyamoto S. PIASy mediates NEMO sumoylation and NF-kappaB activation in response to genotoxic stress. Nature Cell Biology. 8: 986-93. PMID 16906147 DOI: 10.1038/ncb1458  1
2006 Chang PY, Draheim K, Kelliher MA, Miyamoto S. NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells. Cancer Research. 66: 6008-13. PMID 16778171 DOI: 10.1158/0008-5472.CAN-06-0194  0.84
2006 Chang PY, Miyamoto S. Nuclear factor-kappaB dimer exchange promotes a p21(waf1/cip1) superinduction response in human T leukemic cells. Molecular Cancer Research : McR. 4: 101-12. PMID 16513841 DOI: 10.1158/1541-7786.MCR-05-0259  0.84
2005 Wuerzberger-Davis SM, Chang PY, Berchtold C, Miyamoto S. Enhanced G2-M arrest by nuclear factor-{kappa}B-dependent p21waf1/cip1 induction. Molecular Cancer Research : McR. 3: 345-53. PMID 15972853 DOI: 10.1158/1541-7786.MCR-05-0028  0.92
2005 O'Connor S, Markovina S, Miyamoto S. Evidence for a phosphorylation-independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IkappaBalpha degradation in B cells. Experimental Cell Research. 307: 15-25. PMID 15922723 DOI: 10.1016/j.yexcr.2005.02.015  0.68
2005 O'Connor S, Shumway S, Miyamoto S. Inhibition of IkappaBalpha nuclear export as an approach to abrogate nuclear factor-kappaB-dependent cancer cell survival. Molecular Cancer Research : McR. 3: 42-9. PMID 15671248  0.48
2004 Bates PW, Miyamoto S. Expanded nuclear roles for IkappaBs. Science's Stke : Signal Transduction Knowledge Environment. 2004: pe48. PMID 15479861 DOI: 10.1126/stke.2542004pe48  0.48
2004 O'Connor S, Shumway SD, Amanna IJ, Hayes CE, Miyamoto S. Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells. Molecular and Cellular Biology. 24: 4895-908. PMID 15143182 DOI: 10.1128/MCB.24.11.4895-4908.2004  0.48
2004 Shumway SD, Miyamoto S. A mechanistic insight into a proteasome-independent constitutive inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor kappaB (NF-kappaB) activation pathway in WEHI-231 B-cells. The Biochemical Journal. 380: 173-80. PMID 14763901 DOI: 10.1042/BJ20031796  0.48
2003 Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell. 115: 565-76. PMID 14651848  0.92
2003 Narayanan K, Krishnamoorthy B, Ezhilarasan R, Miyamoto S, Balakrishnan A. Targeting apoptotic signalling pathway and pro-inflammatory cytokine expression as therapeutic intervention in TPE induced lung damage. Cell Biology International. 27: 375-82. PMID 12788054 DOI: 10.1016/S1065-6995(03)00014-3  0.48
2002 Huang TT, Feinberg SL, Suryanarayanan S, Miyamoto S. The zinc finger domain of NEMO is selectively required for NF-kappa B activation by UV radiation and topoisomerase inhibitors. Molecular and Cellular Biology. 22: 5813-25. PMID 12138192 DOI: 10.1128/MCB.22.16.5813-5825.2002  0.48
2002 Narayanan K, Seufzer BJ, Brockman-Schneider RA, Gern JE, Balakrishnan A, Miyamoto S. CD14-dependent activation of NF-kappaB by filarial parasitic sheath proteins. Cell Biology International. 26: 43-54. PMID 11779220 DOI: 10.1006/cbir.2001.0828  0.48
2002 Shumway SD, Berchtold CM, Gould MN, Miyamoto S. Evidence for unique calmodulin-dependent nuclear factor-kappaB regulation in WEHI-231 B cells. Molecular Pharmacology. 61: 177-85. PMID 11752219 DOI: 10.1124/mol.61.1.177  0.48
2000 Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, Boothman DA, Miyamoto S. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. The Journal of Biological Chemistry. 275: 9501-9. PMID 10734098 DOI: 10.1074/jbc.275.13.9501  0.48
2000 Yang CR, Wilson-Van Patten C, Planchon SM, Wuerzberger-Davis SM, Davis TW, Cuthill S, Miyamoto S, Boothman DA. Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 14: 379-90. PMID 10657994  0.92
1999 Shumway SD, Maki M, Miyamoto S. The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain. The Journal of Biological Chemistry. 274: 30874-81. PMID 10521480 DOI: 10.1074/jbc.274.43.30874  0.48
1998 Miyamoto S, Seufzer BJ, Shumway SD. Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells. Molecular and Cellular Biology. 18: 19-29. PMID 9418849  0.48
Show low-probability matches.